SU5416
(semaxanib)Phase 3Small molecule
PfizerSemaxanib was investigated as a cancer treatment that works by blocking blood vessel formation in tumors, which aims to starve cancer cells of oxygen and nutrients they need to grow.[1] SU5416 is currently being investigated across 16 indications[3], with its most advanced program in Phase 3.[1]
SU5416 is one of 419 small molecule programs targeting Mixed Glioma. It is currently in Phase 3.
16
Indications
27
Total Trials
0
Active Trials
418
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 16 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1SU5416
PfizerPhase 3
Prolia
AmgenPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
MS Contin
Merck & Co.Preclinical
Adenocard
AstellasPreclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Zinecard
CChildren's Oncology Group
Preclinical
Acupan
YYonsei University
Preclinical
Paracetamol
GSKPreclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Patients With Advanced Solid Tumors3 trials
SU5416 in Treating Patients With Advanced Solid Tumors
Completed·—·Phase 1·NCT00005642·19 enrolled
Soft Tissue Sarcoma3 trials
Colorectal Cancer2 trials
Cancer of the Head and Neck2 trials
12 more indications
Kidney Cancer2 trials
Kaposi's sarcoma2 trials
Metastatic Colorectal Cancer2 trials
Mixed Glioma1 trial
Advanced Cancer1 trial
SU5416 and Paclitaxel in Treating Patients With Advanced Cancer
Completed·—·Phase 1·NCT00006257
Hematologic Cancer1 trial
Breast Cancer1 trial
SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer
Completed·—·Phase 1·NCT00005822·21 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for semaxanib. EMBL-EBI & Wellcome Sanger Institute.
- [4]